Literature DB >> 26956262

Erratum to: The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

D T Blumenthal1, L Mendel2, F Bokstein3.   

Abstract

Entities:  

Year:  2016        PMID: 26956262     DOI: 10.1007/s11060-016-2100-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  1 in total

1.  Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.

Authors:  Anne Hertenstein; Thomas Hielscher; Oliver Menn; Benedikt Wiestler; Frank Winkler; Michael Platten; Wolfgang Wick; Antje Wick
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.